NASDAQ:CHMA

Chiasma Competitors

$2.91
+0.03 (+1.04 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.87
Now: $2.91
$3.00
50-Day Range
$2.82
MA: $3.32
$4.06
52-Week Range
$2.77
Now: $2.91
$7.75
Volume482,688 shs
Average Volume1.68 million shs
Market Capitalization$168.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59

Competitors

Chiasma (NASDAQ:CHMA) Vs. CALT, KDMN, CLVS, GOSS, RIGL, and RLMD

Should you be buying CHMA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Chiasma, including Calliditas Therapeutics AB (publ) (CALT), Kadmon (KDMN), Clovis Oncology (CLVS), Gossamer Bio (GOSS), Rigel Pharmaceuticals (RIGL), and Relmada Therapeutics (RLMD).

Chiasma (NASDAQ:CHMA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Chiasma and Calliditas Therapeutics AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chiasma00203.00
Calliditas Therapeutics AB (publ)00503.00

Chiasma currently has a consensus price target of $11.6667, suggesting a potential upside of 300.92%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, suggesting a potential upside of 51.39%. Given Chiasma's higher probable upside, research analysts plainly believe Chiasma is more favorable than Calliditas Therapeutics AB (publ).

Institutional & Insider Ownership

71.3% of Chiasma shares are owned by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 5.5% of Chiasma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Chiasma and Calliditas Therapeutics AB (publ)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChiasmaN/AN/A$-36,320,000.00($1.06)-2.75
Calliditas Therapeutics AB (publ)$19.56 million34.41$-3,450,000.00($0.19)-141.84

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Chiasma. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Chiasma and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChiasmaN/A-83.82%-56.55%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Summary

Calliditas Therapeutics AB (publ) beats Chiasma on 6 of the 10 factors compared between the two stocks.

Chiasma (NASDAQ:CHMA) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Risk & Volatility

Chiasma has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Kadmon has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Earnings and Valuation

This table compares Chiasma and Kadmon's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChiasmaN/AN/A$-36,320,000.00($1.06)-2.75
Kadmon$5.09 million131.65$-61,370,000.00($0.74)-5.27

Chiasma has higher earnings, but lower revenue than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Chiasma and Kadmon, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chiasma00203.00
Kadmon00503.00

Chiasma currently has a consensus target price of $11.6667, suggesting a potential upside of 300.92%. Kadmon has a consensus target price of $12.75, suggesting a potential upside of 226.92%. Given Chiasma's higher possible upside, analysts plainly believe Chiasma is more favorable than Kadmon.

Profitability

This table compares Chiasma and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChiasmaN/A-83.82%-56.55%
Kadmon-768.36%-85.07%-46.46%

Insider and Institutional Ownership

71.3% of Chiasma shares are owned by institutional investors. Comparatively, 94.8% of Kadmon shares are owned by institutional investors. 5.5% of Chiasma shares are owned by insiders. Comparatively, 3.0% of Kadmon shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Chiasma (NASDAQ:CHMA) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Risk and Volatility

Chiasma has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.

Institutional and Insider Ownership

71.3% of Chiasma shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 5.5% of Chiasma shares are held by insiders. Comparatively, 6.6% of Clovis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Chiasma and Clovis Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChiasmaN/A-83.82%-56.55%
Clovis Oncology-230.34%N/A-57.56%

Analyst Recommendations

This is a summary of recent recommendations for Chiasma and Clovis Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chiasma00203.00
Clovis Oncology22202.00

Chiasma currently has a consensus target price of $11.6667, suggesting a potential upside of 300.92%. Clovis Oncology has a consensus target price of $9.50, suggesting a potential upside of 52.00%. Given Chiasma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Chiasma is more favorable than Clovis Oncology.

Valuation and Earnings

This table compares Chiasma and Clovis Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChiasmaN/AN/A$-36,320,000.00($1.06)-2.75
Clovis Oncology$143.01 million4.57$-400,420,000.00($7.60)-0.82

Chiasma has higher earnings, but lower revenue than Clovis Oncology. Chiasma is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Chiasma beats Clovis Oncology on 7 of the 12 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Insider and Institutional Ownership

72.0% of Gossamer Bio shares are owned by institutional investors. Comparatively, 71.3% of Chiasma shares are owned by institutional investors. 23.3% of Gossamer Bio shares are owned by insiders. Comparatively, 5.5% of Chiasma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Gossamer Bio and Chiasma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gossamer BioN/A-64.34%-46.52%
ChiasmaN/A-83.82%-56.55%

Earnings and Valuation

This table compares Gossamer Bio and Chiasma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.59
ChiasmaN/AN/A$-36,320,000.00($1.06)-2.75

Chiasma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gossamer Bio has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Gossamer Bio and Chiasma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gossamer Bio00503.00
Chiasma00203.00

Gossamer Bio currently has a consensus price target of $23.00, indicating a potential upside of 169.64%. Chiasma has a consensus price target of $11.6667, indicating a potential upside of 300.92%. Given Chiasma's higher probable upside, analysts clearly believe Chiasma is more favorable than Gossamer Bio.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Earnings and Valuation

This table compares Rigel Pharmaceuticals and Chiasma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$59.29 million10.70$-66,890,000.00($0.40)-9.33
ChiasmaN/AN/A$-36,320,000.00($1.06)-2.75

Chiasma has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 71.3% of Chiasma shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Chiasma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Rigel Pharmaceuticals and Chiasma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rigel Pharmaceuticals01302.75
Chiasma00203.00

Rigel Pharmaceuticals currently has a consensus target price of $8.3333, indicating a potential upside of 123.41%. Chiasma has a consensus target price of $11.6667, indicating a potential upside of 300.92%. Given Chiasma's stronger consensus rating and higher possible upside, analysts plainly believe Chiasma is more favorable than Rigel Pharmaceuticals.

Profitability

This table compares Rigel Pharmaceuticals and Chiasma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rigel Pharmaceuticals-26.25%-44.96%-20.08%
ChiasmaN/A-83.82%-56.55%

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Summary

Chiasma beats Rigel Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Relmada Therapeutics (NASDAQ:RLMD) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for Relmada Therapeutics and Chiasma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relmada Therapeutics01202.67
Chiasma00203.00

Relmada Therapeutics currently has a consensus price target of $63.3333, suggesting a potential upside of 72.24%. Chiasma has a consensus price target of $11.6667, suggesting a potential upside of 300.92%. Given Chiasma's stronger consensus rating and higher probable upside, analysts clearly believe Chiasma is more favorable than Relmada Therapeutics.

Risk & Volatility

Relmada Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Institutional & Insider Ownership

64.3% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 71.3% of Chiasma shares are owned by institutional investors. 9.3% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Chiasma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Relmada Therapeutics and Chiasma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relmada TherapeuticsN/A-32.03%-31.41%
ChiasmaN/A-83.82%-56.55%

Valuation & Earnings

This table compares Relmada Therapeutics and Chiasma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/AN/A($2.16)-17.13
ChiasmaN/AN/A$-36,320,000.00($1.06)-2.75

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Summary

Chiasma beats Relmada Therapeutics on 6 of the 9 factors compared between the two stocks.


Chiasma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.95+0.9%$672.97 million$19.56 million-19.39
Kadmon logo
KDMN
Kadmon
1.8$3.90+7.2%$670.09 million$5.09 million-6.50Analyst Downgrade
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.25+1.8%$653.31 million$143.01 million-1.19
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.53+1.4%$644.25 millionN/A-2.40High Trading Volume
Increase in Short Interest
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.73+3.2%$634.55 million$59.29 million-24.87Increase in Short Interest
News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$37.00+2.8%$619.64 millionN/A-17.13
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.39+0.6%$619.10 million$9.64 million-5.28News Coverage
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.79+3.6%$606.17 millionN/A-9.99Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$24.92+4.9%$605.76 million$12.69 million-11.98Increase in Short Interest
OrganiGram logo
OGI
OrganiGram
1.6$2.60+11.9%$603.91 million$64.61 million-3.82Earnings Announcement
Analyst Report
Decrease in Short Interest
News Coverage
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.15+11.7%$594.69 millionN/A-4.48Analyst Upgrade
Analyst Revision
News Coverage
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$13.80+0.8%$584.80 million$17.26 million-3.83Analyst Revision
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$43.37+2.9%$573.22 million$195.89 million123.92
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.64+3.4%$567.03 millionN/A-5.42
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.27+3.6%$561.28 million$8 million-7.85
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.85+4.6%$543.18 millionN/A-4.28
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.42+2.4%$542.34 million$1.19 million-6.84
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.01+4.0%$541.92 millionN/A-4.77
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$6.99+0.6%$539.54 million$26.74 million17.48
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.75+3.3%$536.73 millionN/A-9.11Increase in Short Interest
News Coverage
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15News Coverage
Inventiva logo
IVA
Inventiva
0.0$13.60+2.9%$525.37 millionN/A0.00News Coverage
Gap Up
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.91+7.7%$519.95 millionN/A-8.23
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.98+2.6%$519.55 millionN/A-5.63
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.15+0.5%$516.80 million$25 million-18.69Analyst Report
Provention Bio logo
PRVB
Provention Bio
1.6$8.13+4.6%$515.24 millionN/A-5.46Analyst Report
Increase in Short Interest
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78+2.7%$513.32 million$59.22 million43.90
Evolus logo
EOLS
Evolus
1.3$11.72+0.5%$512.55 million$34.92 million-5.77Analyst Report
XBiotech logo
XBIT
XBiotech
1.0$16.89+1.2%$497.56 millionN/A1.17
AC Immune logo
ACIU
AC Immune
1.3$6.87+2.9%$494.21 million$111.75 million-7.63
Akouos logo
AKUS
Akouos
1.6$14.36+1.3%$494.01 millionN/A0.00News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.89+1.2%$492.23 million$58.12 million-16.15Decrease in Short Interest
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$36.38+4.8%$491.46 million$40,000.00-1.58
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.22+0.8%$490.51 million$49.65 million-1.72Analyst Upgrade
Altimmune logo
ALT
Altimmune
1.9$12.95+2.2%$481.09 million$5.80 million-6.51Increase in Short Interest
Geron logo
GERN
Geron
1.4$1.51+5.3%$480.98 million$460,000.00-4.31Decrease in Short Interest
News Coverage
Gap Down
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.12+2.9%$478.16 million$335 million-1.05
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.20+0.2%$475.07 millionN/A-2.49
89bio logo
ETNB
89bio
1.6$23.78+1.1%$474.32 millionN/A-4.71
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$9.38+0.3%$468.04 million$72.96 million-3.03Analyst Report
High Trading Volume
News Coverage
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.22+5.4%$467.74 million$57.49 million-6.07Increase in Short Interest
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.46+1.8%$463.06 million$102.31 million6.66Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.25+4.6%$462.43 million$22.27 million-4.04Insider Buying
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.56+3.2%$461.01 million$56.50 million0.00
Verastem logo
VSTM
Verastem
1.3$2.68+0.7%$460.07 million$17.46 million-1.90Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.99+0.7%$458.88 million$109.33 million-2.19Analyst Report
Gap Down
BCEL
Atreca
1.7$12.42+6.4%$457.44 millionN/A-4.40News Coverage
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.00+1.7%$444.80 millionN/A-12.24
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.89+1.1%$443.24 millionN/A0.00News Coverage
Gap Down
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.21+0.7%$440.71 million$6.07 million-3.45News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.